currency exchange  - Risk-Free High Returns Strategy
currency exchange  - Risk-Free High Returns Strategy
currency exchange  - Risk-Free High Returns Strategy
currency exchange  - Risk-Free High Returns Strategy
currency exchange  - Risk-Free High Returns Strategy
currency exchange  - Risk-Free High Returns Strategy
currency exchange  - Risk-Free High Returns Strategy
currency exchange  - Risk-Free High Returns Strategy

currency exchange - Risk-Free High Returns Strategy

₹1734

currency exchange ✌️【Working Hours】✌️Invest ₹500 in our safe platform and start earning passive income every month.

quantity
Add to Wishlist
Product Description

currency exchange ✌️【Working Hours】✌️Invest ₹500 in our safe platform and start earning passive income every month.

currency exchange ✌️【Working Hours】✌️Invest ₹500 in our safe platform and start earning passive income every month.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

currency exchange ✌️【Working Hours】✌️Low risk, high rewards. Start your investment with ₹500 and earn up to 100% monthly!We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

currency exchange ✌️【Working Hours】✌️Small investments, big results! ₹500 can earn you up to 100% in just 30 days.The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

currency exchange ✌️【Working Hours】✌️Start investing with ₹500 and experience up to 100% returns every month!The underperformance persists despite a 22.currency exchange Turn ₹500 into Big Returns: Start Investing Today

Related Products